ASCO 2024: T-DXd in Previously Treated Patients With Metastatic Breast Cancer
Posted: 06/12/2024 | By: Chase Doyle

The DESTINY-Breast06 trial evaluated fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with hormone receptor (HR)-positive, HER2-low or -ultralow metastatic breast cancer after disease progression on endocrine-based therapy. Results were presented by Curigliano et al at the 2024 ASCO Annual Meeting (Abstract LBA1000).

Question 1 of 5

What was the primary endpoint of the DESTINY-Breast06 study?

Choose 1